Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ATTO | PRESS-RELEASE | neutral | 3/10 | Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline at | Sep 28, 2026 |
| TEVA | PRESS-RELEASE | bullish | 7/10 | Teva announced FDA approval of DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab) for preventing bone complic | Sep 28, 2026 |
| CELU | SC 13D/A | bearish | 7/10 | The Philip & Daniele Barach Family Trust filed Amendment No. 3 to its Schedule 13D, reporting a significant escalation i | Sep 28, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Sep 28, 2026 |
| ONCY | 8-K | neutral | 4/10 | Oncolytics Biotech reported accelerating enrollment in its REO 033 Phase 2 study of pelareorep in RAS-mutant, MSS metast | Sep 28, 2026 |
| LFCR | DEFA14A | bullish | 7/10 | Lifecore Biomedical entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Partners | Sep 28, 2026 |
| KOD | 8-K | bullish | 7/10 | Kodiak Sciences announced positive topline Phase 3 DAYBREAK results for both Zenkuda (tarcocimab tedromer) and tabirafus | Sep 28, 2026 |
| LFCR | 8-K | bullish | 8/10 | Lifecore Biomedical has entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Part | Sep 28, 2026 |
| SLXN | 8-K | neutral | 4/10 | Silexion Therapeutics reported positive preclinical in vitro findings for its lead siRNA candidate SIL204, demonstrating | Sep 28, 2026 |
| ANIX | CLUSTER | bullish | 4/10 | Two Anixa insiders, including the CEO and a director, made open-market purchases totaling $151K in late September 2026. | Sep 28, 2026 |
| LFCR | PRESS-RELEASE | bullish | 7/10 | Lifecore Biomedical announced it will be acquired by Webster Equity Partners in a take-private transaction. The deal pro | Sep 28, 2026 |
| NEOG | DEFA14A | neutral | 2/10 | Neogen filed a DEFA14A supplement to correct a typographical error in Appendix B of its August 21, 2026 proxy statement. | Sep 28, 2026 |
| SLXN | PRESS-RELEASE | neutral | 3/10 | Silexion Therapeutics announced translational research data showing its SIL204 candidate leverages native serum lipids f | Sep 28, 2026 |
| RNAZ | 8-K | bullish | 6/10 | TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138, showing a 71.4% stable disease rate in 14 | Sep 28, 2026 |
| ACET | 8-K | bullish | 7/10 | Adicet Bio reported positive Phase 1 safety and efficacy data for prula-cel (formerly ADI-001), an allogeneic gamma delt | Sep 28, 2026 |
| FATE | 8-K | bullish | 5/10 | Fate Therapeutics received a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to s | Sep 28, 2026 |
| MIRM | 8-K | bullish | 7/10 | Mirum Pharmaceuticals announced FDA approval of Atebrioz (zilurgisertib) for FOP and positive Phase 3 AZURE-1 data for b | Sep 28, 2026 |
| KROS | 8-K | neutral | 4/10 | Keros Therapeutics announced the first patient was dosed in its Phase 2 clinical trial of rinvatercept for Duchenne musc | Sep 28, 2026 |
| AIMD | 8-K | bullish | 5/10 | Ainos entered into a global exclusive license agreement with BioPhoenix Co., Ltd. for its VELDONA low-dose oral interfer | Sep 28, 2026 |
| MTNB | 8-K | neutral | 4/10 | Matinas BioPharma filed a Certificate of Amendment to effect a 1-for-15 reverse stock split, effective September 28, 202 | Sep 28, 2026 |
| KROS | PRESS-RELEASE | neutral | 3/10 | Keros Therapeutics announced the first patient dosed in a Phase 2 clinical trial of rinvatercept for Duchenne muscular d | Sep 28, 2026 |
| ALXO | PRESS-RELEASE | mixed | 5/10 | ALX Oncology published Phase 2 ASPEN-06 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs 26.6% | Sep 28, 2026 |
| ALLR | PRESS-RELEASE | neutral | 3/10 | Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line res | Sep 28, 2026 |
| NKTR | SC 13G/A | neutral | 4/10 | Two Seas Capital LP filed an amended Schedule 13G disclosing a 9.8% passive stake in Nektar Therapeutics as of September | Sep 28, 2026 |
| IMRX | PRESS-RELEASE | bullish | 6/10 | Immuneering presented exploratory Phase 2a data at AACR Pancreatic Cancer 2026 showing that pancreatic cancer patients o | Sep 28, 2026 |
| SCYX | PRESS-RELEASE | bullish | 6/10 | SCYNEXIS announced a BARDA contract worth up to ~$214M (if all options exercised) to fund development of SCY-247, its se | Sep 28, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber filed an 8-K/A providing audited financials for its Bridgeport manufacturing acquisition, confirming a $4. | Sep 28, 2026 |
| ETON | 8-K | bullish | 5/10 | Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO (miltefosine) capsules, a treatment for leishmania | Sep 28, 2026 |
| IVA | 6-K | mixed | 6/10 | Inventiva reported H1 2026 financial results showing a net loss of €69.5 million, improved from €175.9 million in H1 202 | Sep 28, 2026 |
| ADXN | 6-K | bearish | 7/10 | Addex Therapeutics reported H1 2026 financial results showing a net loss of CHF 3.5 million (vs CHF 3.3 million in H1 20 | Sep 28, 2026 |